Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use

[1]  H. Liszka.  NICE (National Institute for Health and Care Excellence) recommendations in the treatment of osteoarthritis , 2020 .

[2]  Hongzi Zhu,et al.  APP , 2019, Proceedings of the Twentieth ACM International Symposium on Mobile Ad Hoc Networking and Computing.

[3]  K. Thorpe,et al.  Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually. , 2018, Health affairs.

[4]  How externalities impact an evaluation of strategies to prevent antimicrobial resistance in health care organizations , 2017, Antimicrobial Resistance & Infection Control.

[5]  M. Friedrich.  Growing Numbers of Refugees Worldwide Are Children. , 2016, JAMA.

[6]  M. Friedrich.  UN Leaders Commit to Fight Antimicrobial Resistance. , 2016, JAMA.

[7]  Direk Limmathurotsakul,et al.  Epidemiology and burden of multidrug-resistant bacterial infection in a developing country , 2016, eLife.

[8]  H. Wertheim,et al.  Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary health care: a randomised controlled trial , 2016, The Lancet. Global health.

[9]  H. Goossens,et al.  Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance. , 2016, The British journal of general practice : the journal of the Royal College of General Practitioners.

[10]  Luke S P Moore,et al.  Antimicrobials: access and sustainable eff ectiveness 2 Understanding the mechanisms and drivers of antimicrobial resistance , 2015 .

[11]  S. Gandra,et al.  Economic burden of antibiotic resistance: how much do we really know? , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  Bryan T Grenfell,et al.  Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. , 2014, The Lancet. Infectious diseases.

[13]  S. Solomon,et al.  Antibiotic resistance threats in the United States: stepping back from the brink. , 2014, American family physician.

[14]  A. Riewpaiboon.  Standard cost lists for health economic evaluation in Thailand. , 2014, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[15]  B. Cooper,et al.  Long-term survival after intensive care unit discharge in Thailand: a retrospective study , 2013, Critical Care.

[16]  G. Doern,et al.  Antimicrobial Stewardship Programs , 2013, Journal of Clinical Microbiology.

[17]  Bevin Cohen,et al.  A Review of Antibiotic Use in Food Animals: Perspective, Policy, and Potential , 2012, Public health reports.

[18]  K. Kaier,et al.  Measuring the Externality of Antibacterial Use from Promoting Antimicrobial Resistance , 2012, PharmacoEconomics.

[19]  M. Lipsitch,et al.  Is methicillin-resistant Staphylococcus aureus replacing methicillin-susceptible S. aureus? , 2011, The Journal of antimicrobial chemotherapy.

[20]  P. Davey,et al.  Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. , 2011, The Journal of antimicrobial chemotherapy.

[21]  P. Davey,et al.  Clinical Impact of Antimicrobial Resistance in European Hospitals: Excess Mortality and Length of Hospital Stay Related to Methicillin-Resistant Staphylococcus aureus Bloodstream Infections , 2011, Antimicrobial Agents and Chemotherapy.

[22]  J. Davies,et al.  Origins and Evolution of Antibiotic Resistance , 1996, Microbiology and Molecular Biology Reviews.

[23]  E. Tacconelli.  Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings , 2009, Current opinion in infectious diseases.

[24]  K. Kaier,et al.  Two Time-Series Analyses of the Impact of Antibiotic Consumption and Alcohol-Based Hand Disinfection on the Incidences of Nosocomial Methicillin-Resistant Staphylococcus aureus Infection and Clostridium difficile Infection , 2009, Infection Control & Hospital Epidemiology.

[25]  H. Goossens,et al.  Antimicrobial Drug Use and Resistance in Europe , 2008, Emerging infectious diseases.

[26]  Anne Mills,et al.  The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis , 2008, BMJ : British Medical Journal.

[27]  D. Evans,et al.  Economic evaluation in health: saving money or improving care? , 2007 .

[28]  W. Bilker,et al.  Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. , 2006, International journal of antimicrobial agents.

[29]  H. Goossens,et al.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study , 2005, The Lancet.

[30]  Stephan Harbarth,et al.  Antibiotic Selection Pressure and Resistance in Streptococcus pneumoniae and Streptococcus pyogenes , 2004, Emerging infectious diseases.

[31]  E. Elbasha.  Deadweight loss of bacterial resistance due to overtreatment. , 2003, Health economics.

[32]  J. Coast,et al.  Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance? , 2002, Health economics.

[33]  J. Mcgowan.  Economic impact of antimicrobial resistance. , 2001, Emerging infectious diseases.

[34]  J. Coast,et al.  An economic perspective on policy to reduce antimicrobial resistance. , 1998, Social science & medicine.

[35]  J. Coast,et al.  Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? , 1996, Health economics.

[36]  C. Phelps.  Bug/Drug Resistance: Sometimes Less is More , 1989, Medical care.

[37]  Injury rates by industry 1970, BLS Report 406, Department of Labor, Bureau of Labor Statistics. , 1972, IMS, Industrial medicine and surgery.